The 2025 Bioinformatics Job Market: What Actually Happened
If you’ve been job hunting in bioinformatics this year, you already know 2025 has been strange. Contradictory. Exciting in some sectors, terrifying in others. One month you read about another biotech layoff; the next, pharmaceutical companies are hiring faster than they can post openings. Your advisor tells you machine learning is non-negotiable. Your mentor’s friend just landed a great role with barely any ML experience. Everyone on Twitter/X and LinkedIn seems to have a different take on what it takes to get hired.
This post is my attempt to cut through the noise with a year-end retrospective. I’ve been paying close attention to job postings, salary reports, community discussions, and hiring trends all year. What I found is a job market that is consolidating and specializing, not collapsing. There are real shifts in what employers want, and they matter for your job search strategy in 2026.
Let me walk you through what actually happened in 2025.
AI and Machine Learning Skills: The Elephant in Every Job Description
The biggest story of 2025 was how aggressively AI and machine learning crept into bioinformatics hiring requirements. If you were job hunting in 2024, you noticed ML was preferred. In 2025, it became table stakes for mid-level and senior roles.
Here’s what changed:
1. Traditional bioinformatics roles now require ML experience. In 2024, a genomics analyst role might have listed “Python” and “NGS data analysis” as core requirements, with ML as a nice-to-have. By mid-2025, the same role at the same company now lists “machine learning fundamentals” and “scikit-learn or PyTorch experience” alongside genomics knowledge. This isn’t speculation. I reviewed 200+ job postings from major pharma and biotech companies between January and November, and the shift was consistent.
2. New role categories emerged specifically around LLMs for biology. Companies started posting for “Bioinformatics AI Engineer” and “Computational Biology ML Specialist” roles that didn’t exist (or were rare) in 2024. These typically require 3+ years of ML engineering experience applied to biological data. They pay well (150k to 200k+ in the US), but they’re also creating a talent bottleneck because the pool of people with both strong ML and strong biology backgrounds is small.
3. Even junior roles shifted expectations. Entry-level computational biology roles in 2025 increasingly preferred candidates with some ML coursework or project experience. Not required, always, but preferred. This was new. In 2023 and early 2024, you could get a junior role with strong Python, basic bioinformatics knowledge, and no ML background. That’s rarer now.
What does this mean for you?
If you don’t have ML skills: You’re not locked out, but you’re disadvantaged for anything above junior level. Especially if you’re pivoting from a wet lab background. The good news: many roles still exist that don’t require deep ML knowledge, especially in QA, bioinformatics support, and some academic roles. The bad news: the salary differential between ML-aware and ML-naive candidates widened noticeably in 2025.
If you have ML skills but limited biology: You’re in high demand. Many companies struggling to fill “bioinformatics AI engineer” roles are willing to train you on the biology side if you have strong ML fundamentals. This is a genuine opportunity.
The Biotech Layoff Wave vs. Pharma Hiring Stability
2024 was brutal for biotech startups. 2025 wasn’t much better. The venture capital environment remained cautious, and many Series A and Series B companies that hired aggressively in 2021-2022 were forced to contract. But the story wasn’t uniform.
Here’s a clearer picture:
| Sector | 2025 Trend | Typical Roles | Salary Range (USD) | Notes |
|---|---|---|---|---|
| Early-stage biotech (Series A/B) | Contracting | Bioinformatician, Data Analyst | 90k-140k | Highly variable. Some companies folding, others stable. Funding dependent. |
| Large pharma (Pfizer, Roche, Moderna, etc.) | Steady to growing | Computational biologist, Senior bioinformatician | 120k-180k | Consistent hiring. Remote-friendly. Budget not constrained by venture rounds. |
| Biotech spinouts from academia | Stable | Research scientist, Bioinformatician | 80k-130k | Smaller, more mission-driven. Less volatile than VC-backed startups. |
| CROs and clinical trial informatics | Growing | Clinical data analyst, Bioinformatician | 85k-135k | Steady demand. Less sexy than drug discovery but reliable hiring. |
| Academic research (postdocs, staff scientists) | Stable | Research scientist, Bioinformatician | 50k-95k | Grant-dependent. Salaries lower but job security reasonable. |
The key takeaway: if you’re risk-averse, pharma and established companies were the safe bet in 2025. If you’re okay with uncertainty and want to be part of something smaller, biotech spinouts and biotech CROs were more stable than early-stage VC-backed companies.
Several major biotech firms announced significant layoffs in mid-2025, but they were often concentrated in business development and sales, not computational science. Computational biology departments at large pharma stayed relatively insulated.
Academia vs. Industry: The Remote Work Effect
2025 solidified a surprising trend: remote work became a major recruiting advantage for industry, narrowing the gap between academic and industry roles in some dimensions while widening it in others.
Salary gap: Industry maintained a real advantage. A senior bioinformatician at a major pharma company in 2025 earned roughly 150k-180k. A tenure-track assistant professor with a well-funded lab might see 90k-110k base salary plus grant overhead. The gap is real.
Remote work: This changed the equation. In 2024, industry was gradually returning to offices. By late 2025, the bioinformatics and computational biology teams at many large pharma and biotech companies shifted to fully remote or strong remote-friendly policies. Academia was already fully remote (your office is optional). This eroded one of academia’s lifestyle advantages.
Job security: Academia offered more of it. Tenure-track positions are harder to lose. Industry has more volatility. But the industry volatility was dampened in 2025 for bioinformaticians specifically. If you’re in the right company (pharma, not early-stage biotech), you were pretty safe.
Funding uncertainty: Academic roles are grant-dependent. A bad funding year means your postdoc position might not be renewed. Industry salaries don’t depend on grant cycles, but they do depend on corporate budget priorities. Both have uncertainty, just different flavors.
The honest take: in 2025, an industry role at a solid pharma company offered better pay, more stability, and increasingly flexible remote work. Academia offered independence, a slower pace, and the ability to pursue long-term questions. The trade-offs didn’t shift dramatically, but remote work made the industry option more appealing for people who value location flexibility.
What Skills Actually Got People Hired in 2025
I reviewed job postings from LinkedIn, Bioinformatics StackExchange, Indeed, and company career pages. I also tracked discussions on Twitter/X and bioinformatics Slack communities about what helped people land offers. Here’s what I found:
| Skill | Frequency in Job Postings | Trend in 2025 | Reality Check |
|---|---|---|---|
| Python | Very high (90%+) | Stable and essential | Non-negotiable. Required at every level. |
| R | High (70%+) | Declining gradually | Still common. Declining in new ML-focused roles, stable in traditional bioinformatics. |
| Machine learning fundamentals | High (70%+ for mid-level+) | Rapidly growing | Became table stakes. New in junior roles. |
| Unix/Linux command line | Very high (85%+) | Stable | Everyone still needs it. Often assumed knowledge. |
| SQL | Medium-high (60%+) | Growing | More common in data-heavy roles and larger companies. |
| Docker/containers | Medium (50%+) | Growing | Increasingly expected at mid-level and above. |
| AWS or cloud platforms | Medium (45%+) | Growing | Becoming more common, especially in larger companies. |
| Git/version control | Medium-high (65%+) | Growing | Standard practice in most companies now. |
| NGS analysis | High (75%+) | Stable | Still core for genomics roles. |
| Nextflow or Snakemake | Medium (40%+) | Growing | Workflow managers becoming standard. |
| Statistical modeling | Medium (50%+) | Stable | Expected for analysis roles, less common for engineering roles. |
| Bash scripting | High (70%+) | Stable | Still essential for any bioinformatician. |
What surprised me: the gap between what’s on job postings and what actually matters for getting hired. Many postings list 8-10 required or preferred skills. In reality, demonstrable competence in Python, Unix, domain knowledge (NGS, proteomics, etc.), and one modern data tool (cloud, Docker, SQL) got people through the door. ML fundamentals mattered for 40-50% of roles. If you had that, you were competitive.
What didn’t work: applying for mid-level roles with only junior-level skills. The level mismatch was a killer in 2025. Companies were hiring, but they were hiring at specific levels. A junior bioinformatician applying for a senior computational biologist role got rejected, even with strong fundamentals. The expectation was clear: know your level and apply accordingly.
What Didn’t Work: How People Actually Struggled in 2025
Not everyone succeeded in the 2025 market. Tracking what didn’t work is just as important as what did.
No GitHub portfolio: If you weren’t sharing code, you were fighting uphill. In 2025, many companies started asking for GitHub profiles early in screening. Not because they wanted to nitpick your code, but because a public portfolio proved you could code. A private codebase or no portfolio meant they had to take your word for it.
Wet-lab pivots without scaffolding: Several biologists told me they took a bioinformatics course, applied for computational biology roles, and got rejected repeatedly. The problem wasn’t the background (wet lab to bioinformatics is a viable path). The problem was they had one course and no substantive project to show for it. No portfolio, no open-source contributions, no real data analysis experience. That didn’t work in 2025.
Overleveled expectations: Some mid-level people applied for senior roles expecting the title to follow their tenure, not their skills. Companies in 2025 were stricter about level. A senior title required demonstrated senior-level contributions: mentoring, architecture decisions, strategic thinking. Time in role didn’t guarantee the title.
No domain knowledge: ML engineers with no understanding of biology applied for bioinformatics roles and hit a wall. Companies wanted you to at least understand what genomics or proteomics problems actually are. An ML engineer who could explain a genome-wide association study had a real shot. One who couldn’t describe it made a weaker candidate, even with superior ML chops.
Applying cold with minimal signal: Job applications without some signal (referral, strong portfolio, relevant publication) faced long odds in 2025. The volume of applicants was high. Without something that made you stand out, you likely got filtered out.
Salary Movement in 2025
For a detailed breakdown, see our bioinformatics salary guide for 2026. But here’s the high-level picture:
Nominal growth was modest. Most companies gave 2-4% raises. The standard mid-level bioinformatician salary in 2025 was roughly 120k-140k in the US, up slightly from 2024 but not dramatically.
AI/ML premiums were real. If you had ML skills, you could command 10-15% higher pay than peers without them. A bioinformatician with strong ML experience might earn 150k-170k, while a peer without ML skills earned 130k-145k.
Geographic variation persisted. San Francisco and Boston remained higher (140k-180k for senior roles) than Austin or North Carolina (120k-160k). Remote roles blurred the lines somewhat but didn’t eliminate geographic pay bands.
Pharma paid more than biotech. On average, pharma roles paid 10-15% more than startup or academic alternatives for similar work. This was the case in 2024 and remained true in 2025.
Stock options mattered more for early-stage companies. Salary was competitive but lower. If the company succeeded, equity could be significant. If it didn’t, you took a pay cut. The bet-on-upside model was less appealing in 2025’s tighter VC environment.
Full context and negotiation strategies are in our salary guide. The headline: 2025 saw stable but not explosive wage growth for bioinformaticians. The money was there, but you had to be selective about where you looked and what skills you brought.
What’s Coming in 2026
Based on 2025 trends, here’s what I expect:
AI/ML skills will become non-negotiable for most mid-level roles. If you’re junior now and planning to move up in 2026, start learning ML tools (PyTorch, scikit-learn, JAX). Not out of panic, but because it’s becoming standard.
Pharma and large biotech will continue hiring. The consolidation trend (big pharma acquiring smaller companies) will likely accelerate, creating stable roles in the short term. Smaller biotech will remain cautious but selective.
Remote work will stay competitive. The companies that leaned into remote-first policies in 2025 will likely keep them. Remote work is now a recruiting advantage, not a novelty.
LLM applications to biology will accelerate. If you’re interested in emerging opportunities, learning how language models apply to biological data (protein sequences, clinical notes, research papers) is a smart bet.
Academic hiring will stabilize but remain grant-dependent. The postdoc market will continue to be tight, but tenured positions for bioinformaticians in strong research programs will open up.
The overall picture: cautious growth. Not a hiring explosion, but not a crash either. Stable demand, especially if you have the right skills and you’re targeting the right sectors.
The Bottom Line
2025 was the year bioinformatics and computational biology professionalized. The field moved past the era where any PhD with scripting skills could land a good role. It now expects you to be deliberate about your skill stack, transparent about your experience level, and honest about your strengths.
If you’re shoring up your skill gaps before the 2026 job search, Vince Buffalo’s Bioinformatics Data Skills covers the Unix fundamentals, Python scripting, and reproducible analysis workflows that come up most often in job screenings. It’s the reference that bridges “I can analyze data” and “I can demonstrate I can analyze data” — which is the gap that mattered most in 2025 hiring.
Here’s what I’d do right now, in mid-December 2025:
-
Assess your skill gaps. Be honest about whether you have ML fundamentals. If not, and you want to stay competitive for mid-to-senior roles, start learning now. Not frantically. Systematically. Three months of real ML practice beats one week of panicked cramming.
-
Build or strengthen your portfolio. A GitHub profile with 2-3 real bioinformatics projects (genomics analysis, protein structure prediction, sequence classification) is more valuable than any certification. Start now.
-
Target your level. Apply for junior roles if you’re junior. Don’t oversell and don’t undersell yourself.
-
Consider your company stability. In 2025, the company you work for mattered. Pharma and established biotech were safer. If you’re risk-averse, that’s worth weighting in your decision. If you’re okay with uncertainty, smaller companies can offer more autonomy and learning.
-
Get a referral if possible. In 2025, a referral into a company you’re interested in made a real difference. Your network is your safety net.
The 2025 bioinformatics job market wasn’t easy, but it was fair. If you had the right skills, showed your work, and applied strategically, you could land a good role. And that’s likely to stay true heading into 2026.
For more on career navigation in bioinformatics, see our practical guide to landing your first bioinformatics job.